Healthcare Industry News: Amgen
News Release - January 31, 2014
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program ManagementWALTHAM, Mass.--(Healthcare Sales & Marketing Network)--ImmunoGen, Inc. (IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric Guempel as Vice President of Product Strategy and Program Management. Mr. Guempel brings to ImmunoGen more than 30 years of experience in the healthcare industry, including extensive experience in commercial functions related to the strategic development of novel oncology products. He reports to Dr. Charles Morris, Executive Vice President and Chief Development Officer of ImmunoGen.
“Eric joins ImmunoGen in a new position we established to enhance the strategic leadership of our proprietary programs, ensuring that as we advance our clinical compounds through proof of concept we implement development strategies for each compound that align with patient and market needs,” commented Dr. Morris.
Mr. Guempel has extensive experience leading cross-functional oncology product teams. He joins ImmunoGen from the Merck Serono division of Merck KGaA, where he was Head of New Therapies and Strategy for the Oncology Franchise. Prior to joining EMD Serono in 2008, Mr. Guempel held positions of increasing responsibility in the Oncology Strategic Business unit of Biogen Idec, including the position of Rituxan® Team Leader. Prior to joining Idec in 2002, he held commercial positions supporting Neupogen®, Neulasta® and other oncology programs at Amgen. Prior to joining the marketing functions in 1998, Mr. Guempel held clinical research-related positions of increasing responsibility at Amgen, Berlex, and Ciba-Geigy (now Novartis). He holds an MS degree in Biology from Seton Hall University and an MBA from Pepperdine University.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla®, Rituxan®, Neupogen® and Neulasta® are registered trademarks of their respective owners.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.